Ensuring of a “Healthy Life Span” for the public is a growth strategy for the Japanese government, and actions for further vitalization of medical-related industries have begun. The “Headquarters for Healthcare Policy” and “Japan Agency for Medical Research and Development (AMED)” were established as centers of research and development, and the Pharmaceutical Affairs Law was amended to the Pharmaceutical and Medical Device Act (PMD Act). Research and development of drugs and medical devices in Japan is being supported in both tangible and intangible ways. The number of new and approved drugs available for the first time in Japan has significantly increased. – See more at: https://www.diaglobal.org/en/conference-listing/meetings/2015/11/12th-annual-meeting-dia-japan-2015#sthash.KdLrNiSV.dpuf
